EricJFeldmanMD
Oncology • South San Francisco, CAHematologic Oncology
Vice President, Clinical Development, GlycoMimetics Inc.
Dr. Feldman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
611 Gateway Blvd
Suite 810
South San Francisco, CA 94080Phone+1 206-773-3568
Education & Training
Westchester Medical CenterFellowship, Hematology and Medical Oncology, 1984 - 1986
New York Medical College (Metropolitan)Residency, Internal Medicine, 1981 - 1984- New York Medical CollegeClass of 1981
Certifications & Licensure
NY State Medical License 1983 - 2025
TX State Medical License 1991 - 1993- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Super Doctor SuperDoctors.com
Clinical Trials
- MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions Start of enrollment: 2008 Jul 31
- Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Start of enrollment: 2009 Oct 01
- Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma Start of enrollment: 2009 Apr 23
- Join now to see all
Publications & Presentations
PubMed
- 387 citationsPhase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukem...Thomas Fischer, Richard Stone, Daniel J. DeAngelo, Ilene Galinsky, Elihu H. Estey
Journal of Clinical Oncology. 2010-10-01 - 44 citationsProposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from ...John Mascarenhas, Mark L. Heaney, Vesna Najfeld, Elizabeth O. Hexner, Omar Abdel-Wahab
Leukemia Research. 2012-12-01 - 59 citationsPrevalence, Management, and Clinical Consequences of QT Interval Prolongation During Treatment With Arsenic TrioxideGail J. Roboz, Ellen K. Ritchie, Rebecca F. Carlin, Michael Samuel, Leanne Gale
Journal of Clinical Oncology. 2014-11-20
Abstracts/Posters
- A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...Eric J. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Ov...Eric J. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Ichnos Sciences Announces Formation of Scientific Advisory Board to Inform Research and Development Strategy in Immuno-OncologyFebruary 28th, 2022- Ichnos Sciences Welcomes Eric Feldman, M.D., as New Chief Medical OfficerNovember 8th, 2021
Amphivena Announces New Key Leadership and AdvisorsSeptember 11th, 2017
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
